BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Thallion Pharmaceuticals Inc. Announces 2010 First Quarter Results


4/13/2010 11:26:42 AM

MONTREAL, QUEBEC--(Marketwire - April 12, 2010) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced its operational and financial results for the 2010 first quarter which ended on February 28, 2010.

Operational Highlights


--  Signed a definitive development and commercialization agreement with LFB
    Biotechnologies (LFB) for Shigamabs®, under which Thallion is eligible
    to receive up to EUR95 million (approximately C$135 million) from LFB.
    The funding includes an up-front licensing fee of EUR1.5 million
    (approximately C$2.1 million), funding for substantially all future
    clinical development costs, as well as potential milestone payments. The
    agreement grants LFB an exclusive license for the commercial rights to
    Shigamabs® in Europe, South America and other territories of strategic
    interest to LFB, including Russia, Turkey, China, South Korea and
    Northern African countries, while Thallion retained the rights for North
    America and the rest of world. Thallion is eligible to receive tiered,
    double digit royalties based on product sales.  
--  Sold its subordinated promissory note in Caprion Proteomics Inc.
    (Caprion) back to Caprion for an immediate cash payment of $1.85
    million, while retaining the Company's approximate 16 percent equity
    interest in Caprion. 
--  Signed a binding lease cancellation agreement related to its redundant
    facility for a one-time cash payment of $1.15 million. 
--  Appointed Dr. Allan Mandelzys to the position of Chief Executive Officer
    and a member of the Board of Directors. 
--  Appointed Lloyd Segal as Executive Chairman of the Board of Directors. 
--  Discontinued its Phase II trial evaluating TLN-4601 as a treatment for
    glioblastoma multiforme (GBM) due to a lack of measurable efficacy after
    analysis of the interim data. 

"In collaboration with LFB, we have already begun preparations to initiate the Phase II study to evaluate Shigamabs® as a treatment for E. coli infections," said Dr. Allan Mandelzys, Chief Executive Officer of Thallion Pharmaceuticals Inc. "We expect to launch the trial in South America during the fourth quarter of calendar 2010 in order to enroll patients during the peak infection season in the southern hemisphere. The funding received by LFB and our primary focus dedicated to Shigamabs® have considerably strengthened our balance sheet and now provides us with a cash runway to complete development without the need to access additional capital."

Financial Highlights

Research and development expenses before tax credits amounted to $1,171,499 in the first quarter of 2010, compared with $2,111,941 in the first quarter of 2009, reflecting a decrease in costs of $940,442. The 2010 research and development expenses included a $365,027 one-time royalty buy-down payment to a shareholder, Sunol Molecular Corporation (Sunol) upon closing of the LFB transaction pursuant to the terms of the Company's amended license agreement with Sunol. The decrease in research and development expenses is primarily due to the suspension of patient enrollment in the Phase II trial evaluating TLN-232 in July 2009 due to an ongoing dispute with the licensor, and the discontinuation of the Phase II GBM trial due to lack of measurable efficacy after analysis of the interim data.

General and administrative expenses amounted to $1,801,198 in the first quarter of 2010, compared with $1,337,424 in the first quarter of 2009. This increase in 2010 is due in part to $305,000 in one-time cash incentive bonuses paid to certain employees pursuant to final execution of the definitive development and license agreement with LFB and one-time severance costs amounting to $234,086.

The Company recorded a net loss of $2,559,367 or $0.08 per share in the first quarter of 2010, compared with $3,238,671 or $0.10 per share in the first quarter of 2009. The decrease in net loss in the first quarter of 2010 compared to the first quarter of 2009 is mainly attributable to reductions in R&D expenses as described above.

As at February 28, 2010, the Company's unrestricted cash position amounted to $11,932,893 which consists of cash and cash equivalents and short-term investments. Tax credits receivable amounted to $651,839. Consequently, the Company's liquidity availability amounted to $12,584,732 compared with $9,073,557 on November 30, 2009. The increase in liquidity is primarily due to the up-front payment and development funding received from LFB following final execution of the development and license agreement signed in February 2010, the collection of the note receivable from Caprion Proteomics Inc. and the collection of investment tax credits receivable, partially offset by the final settlement of the Company's lease obligations in relation to the redundant facility.

As of April 12, 2010, the Company had 32,194,566 common shares outstanding and a total of 2,453,675 stock options at an average exercise price of $0.13 remain outstanding following the exercise of 38,750 employee stock options in March 2010. A total of 530,000 common share purchase warrants remain outstanding following the expiry of 9,000,000 warrants on March 15, 2010 related to the March 2007 private placement.

Notice of Annual General Meeting of Shareholders

Thallion will hold its Annual General Meeting of Shareholders on, April 13, 2010, at 10:00 a.m. (ET) at the offices of McCarthy Tetrault LLP, Suite 2500, 1000, De La Gauchetiere Street West, Montreal, Quebec. Following the formal proceedings of the meeting, Dr. Allan Mandelzys, Chief Executive Officer will present a corporate update on the Company.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical programs include Shigamabs® and TLN-4601, a novel anti-cancer therapy. Shigamabs® is a dual antibody product for the treatment of Shiga toxin producing E. coli bacterial infections which is anticipated to enter Phase II clinical testing in the fourth quarter of 2010. Additional information about Thallion can be obtained at www.thallion.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect Thallion's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the satisfaction of conditions provided in the development and commercialization agreement with LFB, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in Thallion's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Thallion undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


THALLION PHARMACEUTICALS INC.                                             
Consolidated Balance Sheets                                               
February 28, 2010 and November 30, 2009                                   
(Unaudited)                                                               
                                              2010            2009 
-------------------------------------------------------------------
Assets                                                             
Current assets:                                                    
  Cash and cash equivalents        $     5,722,951 $     1,665,929 
  Short-term investments                 6,209,942       5,910,559 
  Restricted cash                                -       1,590,024 
  Sales tax and other receivable           374,534         252,935 
  Tax credits receivable                   314,038       1,159,268 
  Receivable from Premium Brands                                   
   Holdings Corporation                    337,801         337,801 
  Receivable from Caprion                                          
   Proteomics Inc.                               -       1,835,000 
  Deposits and prepaid expenses            630,087         465,971 
-------------------------------------------------------------------
                                        13,589,353      13,217,487 
Long-term deposit                          100,000         100,000 
Restricted cash                          1,000,000       1,000,000 
Capital assets                             198,779         214,202 
-------------------------------------------------------------------
                                   $    14,888,132 $    14,531,689 
-------------------------------------------------------------------
                                                                   
Liabilities and Shareholders'                                      
 Equity                                                            
Current liabilities:                                               
  Accounts payable and accrued                                     
   liabilities                     $     1,590,016 $     1,482,111 
  Current portion of lease exit                                    
   obligations                             474,315       1,397,494 
-------------------------------------------------------------------
                                         2,064,331       2,879,605 
                                                                   
Long-term portion of lease exit                                    
 obligations                             1,808,193       1,925,531 
Deferred revenues                        3,828,004               - 
                                                                   
Shareholders' Equity:                                              
  Capital stock                        115,504,103     115,502,723 
  Warrants                               9,986,860       9,986,860 
  Contributed surplus                   11,510,115      11,491,077 
                                                                   
  Deficit                             (129,813,474)   (127,254,107)
                                                                   
                                   --------------------------------
  Total shareholders' equity             7,187,604       9,726,553 
                                                                   
-------------------------------------------------------------------
                                   $    14,888,132 $    14,531,689 
-------------------------------------------------------------------
                                                                   
                                                                   
                                                                   
THALLION PHARMACEUTICALS INC.                                             
Consolidated Statements of Operations                                     
Three-month periods ended February 28, 2010 and 2009                      
(Unaudited)                                                               


                                                2010             2009 
----------------------------------------------------------------------
Revenues                                                              
  Collaboration and licensing                                         
   revenues                          $        36,000  $             - 
  Interest revenues                           19,217           37,047 
----------------------------------------------------------------------
                                              55,217           37,047 
Costs and expenses                                                    
  Research and development                 1,171,499        2,111,941 
  Tax credits                               (347,988)        (287,719)
----------------------------------------------------------------------
                                             823,511        1,824,222 
                                                                      
  General and administrative               1,801,198        1,337,424 
  Amortization of capital assets              14,327          124,235 
  Foreign exchange gain                      (24,452)         (10,163)
----------------------------------------------------------------------
                                           2,614,584        3,275,718 
----------------------------------------------------------------------
                                                                      
Net loss                             $    (2,559,367) $    (3,238,671)
----------------------------------------------------------------------
                                                                      
Net basic and diluted                                                 
loss per share                       $         (0.08) $         (0.10)
                                     ---------------------------------
                                                                      
Weighted average number                                               
of outstanding shares                     32,145,849       32,144,316 
                                     ---------------------------------
                                                                      
                                                                      
                                                                      
Consolidated Statements of Comprehensive Loss                             
Three-month periods ended February 28, 2010 and 2009                      
(Unaudited)                                                               
                                                                  
                                              2010           2009 
------------------------------------------------------------------
Net loss                             $  (2,559,367) $  (3,238,671)
Other comprehensive loss                                          
  Unrealized gain on available for                                
   sale investments                             -             265 
                                     -----------------------------
Comprehensive loss                   $  (2,559,367) $  (3,238,406)
------------------------------------------------------------------
                                                                  
                                                                  
                                                                  
THALLION PHARMACEUTICALS INC.                                             
Consolidated Statements of Cash Flows                                     
Three-month periods ended February 28, 2010 and 2009                      

                                              2010           2009 
                                     -----------------------------
Cash flows from operating activities:                             
Net loss                             $  (2,559,367) $  (3,238,671)
Adjustments for:                                                  
  Accretion in carrying value of                                  
   lease liability                         132,243         77,294 
  Amortization of capital assets            14,327        124,235 
  Gain on disposal of short-term                                  
   investments                                   -        (14,013)
  Stock-based compensation                  19,038        111,730 
------------------------------------------------------------------
                                        (2,393,759)    (2,939,425)
Changes in operating assets and                                   
 liabilities:                                                     
  Sales tax and other receivable          (115,333)       (14,698)
  Interest receivable                       (6,266)         1,470 
  Tax credits receivable                   845,230       (287,719)
  Receivable from Caprion Proteomics                              
   Inc.                                  1,835,000              - 
  Deposits and prepaid expenses           (164,116)       (59,821)
  Accounts payable and accrued                                    
   liabilities                             107,905        279,037 
  Deferred revenues                      3,828,004              - 
  Sub-lease revenues collected             227,397              - 
  Payment of lease exit obligations     (1,400,157)      (160,267)
------------------------------------------------------------------
                                         5,157,664       (241,998)
------------------------------------------------------------------
                                         2,763,905     (3,181,423)
------------------------------------------------------------------
                                                                  
Cash flows from financing activities:                             
Issuance of common shares                    1,380              - 
------------------------------------------------------------------
                                             1,380              - 
------------------------------------------------------------------
                                                                  
Cash flows from investing activities:                             
Acquisition of short-term investments     (299,383)       (23,498)
Proceeds from disposal of short-term                              
 investments                                     -      1,014,296 
Restricted cash                          1,590,024              - 
Additions to capital assets                      -        (16,309)
Proceeds from disposal of capital                                 
 assets                                      1,096              - 
------------------------------------------------------------------
                                         1,291,737        974,489 
------------------------------------------------------------------
                                                                  
Net increase (decrease) in cash and                               
 cash equivalents                        4,057,022     (2,206,934)
Cash and cash equivalents, beginning                              
 of period                               1,665,929      8,863,383 
------------------------------------------------------------------
Cash and cash equivalents, end of                                 
 period                              $   5,722,951  $   6,656,449 
------------------------------------------------------------------


Contacts:
Thallion Pharmaceuticals Inc.
Michael Singer
Chief Financial Officer
514-940-3600
514-228-3622 (FAX)
info@thallion.com
www.thallion.com

Investor Relations
The Equicom Group Inc.
Ross Marshall
416-815-0700 (Ext. 238)
416-815-0080 (FAX)
rmarshall@equicomgroup.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES